Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “therapy”

782 pharma patents match "therapy" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 782
Index total 30,257
Page 3 / 33

Quick answer

This filtered view shows 782 pharmaceutical patents matching "therapy" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

782 results for “therapy” · 30,257 patents in full index Clear search

  1. US 12214218

    Perfusion modulated tumor dose sculpting with single dose radiotherapy

    FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  2. US 12201658

    Viral gene therapy as treatment for cholesterol storage disease or disorder

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  3. US 12201655

    Antimicrobial therapy

    The Regents of the University of California · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  4. US 12201719

    Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

    VACCINEX, INC. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  5. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  6. US 12194016

    Methods of providing solriamfetol therapy to subjects with impaired renal function

    AXSOME MALTA LTD. · Granted Jan 14, 2025 · Expires Jan 9, 2045

    granted
  7. US 12186428

    Combination taxoid nanoemulsion with immunotherapy in cancer

    Northwestern University · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  8. US 12186369

    Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, in arrhythmogenic right ventricular cardiomyopathy

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  9. US 2025002606

    Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA

    BAVARIAN NORDIC AS [DK] · Granted Jan 2, 2025 · Expires Dec 28, 2044

    granted
  10. US 12178787

    T cell receptors for immunotherapy

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  11. US 12173314

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    United States Government as represented by the Department of Veterans Affairs · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  12. US 12170134

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 17, 2024 · Expires Dec 12, 2044

    granted
  13. US 12161733

    Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 10, 2024 · Expires Dec 5, 2044

    granted
  14. US 12156879

    Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

    UNIVERSITY OF CONNECTICUT · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  15. US 12156863

    Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

    Galera Labs, LLC · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  16. US 12159700

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Dec 3, 2024 · Expires Nov 28, 2044

    granted
  17. US 12151001

    Optimized expression cassettes for gene therapy

    Tenaya Therapeutics, Inc. · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  18. US 12152242

    CRISPR therapy

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Nov 26, 2024 · Expires Nov 21, 2044

    granted
  19. US 12121540

    CBL inhibitors and compositions for use in adoptive cell therapy

    NURIX THERAPEUTICS, INC. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  20. US 12121580

    Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

    The Board of Regents of the University of Texas System · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  21. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Oct 22, 2024 · Expires Oct 17, 2044

    granted
  22. US 12115163

    Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

    IDEAYA Biosciences, Inc. · Granted Oct 15, 2024 · Expires Oct 10, 2044

    granted
  23. US 12110504

    Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes

    United States Government as represented by the Department of Veterans Affairs · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted
  24. US 12110334

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    The Regents of the University of California · Granted Oct 8, 2024 · Expires Oct 3, 2044

    granted